Background Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …

Background: Urothelial bladder carcinomas had traditionally been difficult to treat cancers,
with high morbidity and mortality rates when invasive and metastatic. In recent years …

PURPOSE Immune checkpoint blockade (ICB) therapy has significantly improved clinical
outcomes in bladder cancer. Identification of correlates of benefit is critical to select …

Background: Bladder urothelial cancer (BLCA) treatment using immune checkpoint
inhibitors (IMCIs) can result in long-lasting clinical benefits. However, only a fraction of …

Purpose: This retrospective analysis of the largest available clinico-genomic database used
de-identified patient-level electronic health record–derived real-world data (RWD) combined …

In recent years, immune checkpoint inhibitors (ICIs) targeting CTLA-4 or PD1/PDL1 have
achieved remarkable success in the treatment of bladder cancer (BLCA), but only a few …

Background Molecular subtyping of urothelial cancer (UC) has significantly advanced the
understanding of bladder tumor heterogeneity and development of prognostic and predictive …

Background Only a proportion of patients with bladder cancer may benefit from durable
response to immune checkpoint inhibitor (ICI) therapy. More precise indicators of response …

Immune checkpoint inhibitors (ICIs) are commonly used to treat patients with advanced
urothelial cancer. However, a significant number of patients do not respond to ICI, and the …

Urothelial bladder cancer (UBC) is one of the most common lethal cancer worldwide and the
5-year survival rate has not improved significantly with current treatment protocols during the …